At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
CC-4047 +2 moredrug
Likely dose
CC-4047 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)
In Brief
A Phase 2 clinical trial evaluating CC-4047 and Prednisone for Polycythemia Vera and Thrombocythemia. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if CC-4047 (now called pomalidomide) and prednisone can help to control MMM. The safety of this therapy will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycythemia Vera, Thrombocythemia
CountriesUnited States
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionMay 2018
TodayJul 2026
First PostedJul 24, 2009
Enrollment StartJul 22, 2009
Primary CompletionMay 22, 2018
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 16.9 years ago
Interventions
CC-4047drug
0.5 mg capsules daily by mouth day 1 through day 28.
Prednisonedrug
30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
CC-4047drug
3.0 mg capsules daily by mouth day 1 through 21.